Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : Aralez Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
Brand Name : Blexten
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2022
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Aralez Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Details : Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estoni...
Brand Name : Suvexx
Molecule Type : Small molecule
Upfront Cash : $2.0 million
December 21, 2020
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
